BTIG Upgrades Organogenesis Hldgs to Buy, Announces $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
BTIG analyst Ryan Zimmerman has upgraded Organogenesis Holdings (NASDAQ:ORGO) from Neutral to Buy and set a $10 price target.
May 24, 2023 | 8:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Organogenesis Holdings (ORGO) has been upgraded from Neutral to Buy by BTIG analyst Ryan Zimmerman, who set a $10 price target.
The upgrade from Neutral to Buy by BTIG analyst Ryan Zimmerman indicates a positive outlook for Organogenesis Holdings. The $10 price target suggests potential upside for the stock, which could lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100